Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13–19] (Thrombosis Research (2020) 185 (13–19), (S0049384819304931), (10.1016/j.thromres.2019.11.007))

F. I. Mulder, N. van Es, N. Kraaijpoel, M. di Nisio, M. Carrier, A. Duggal, M. Gaddh, D. Garcia, M. A. Grosso, A. K. Kakkar, M. F. Mercuri, S. Middeldorp, G. Royle, A. Segers, S. Shivakumar, P. Verhamme, T. Wang, J. I. Weitz, G. Zhang, H. R. BüllerG. Raskob

Research output: Contribution to journalErratum/CorrigendumAcademic

2 Citations (Scopus)


The authors regret that panel E of Fig. 1 was missing, showing the cumulative incidence of the primary outcome in hematologic cancer. The authors would like to apologise for any inconvenience caused.
Original languageEnglish
Pages (from-to)156-159
Number of pages4
JournalThrombosis research
Publication statusPublished - Jul 2020

Cite this